Announcement PDF RNS Number : 2986C Shield Therapeutics PLC 18 June 2021 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Directorate Change London, UK, 18 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that further to the announcement issued on 28 May 2021, Greg Madison will join the Board with immediate effect and is fulfilling the role of the Group's Chief Executive Officer. Shield also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies. Full name: Gregory Paul Madison Age: 53 years Current directorships/partnerships: · American Kidney Fund, Board of Trustees Previous directorships/partnerships held in the past 5 years: · Melt Pharmaceuticals, Inc. · Keryx Biopharmaceuticals, Inc. · Keryx Biopharma UK Ltd. Mr Madison currently does not hold any ordinary shares in Shield. There are no other disclosures required in connection with the appointment of Mr Madison under Schedule Two(g) of the Aim Rules for Companies. For further information please contact: Shield Therapeutics plc Greg Madison, CEO Lucy Huntington-Bailey Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Christopher Golden www.shieldtherapeutics.com +44 (0) 191 511 8500 +44 (0)20 7418 8900 Joint Broker finnCap Ltd Geoff Nash/Alice Lane/George Dollemore Financial PR & IR Advisor Walbrook PR +44 (0)20 7220 0500 +44 (0)20 7933 8780 or shield@walbrookpr.com Paul McManus/Lianne Cawthorne About Shield Therapeutics plc Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END BOAMZGMVKNLGMZM